## Edgar Filing: bluebird bio, Inc. - Form 4

bluebird bio, Inc. Form 4 December 17, 2017 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations any continue. See Instruction 1(b).						
<ul> <li>(Print or Type Responses)</li> <li>1. Name and Address of Reporting Person <sup>*</sup></li> <li>Davidson David</li> <li>(Last) (First) (Middle)</li> <li>(Last) (First) (Middle)</li> <li>Date of Ea (Month/Day/</li> <li>C/O BLUEBIRD BIO, INC., 150 12/15/2015</li> <li>SECOND STREET</li> </ul>				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title 0ther (specify below) Chief Medical Officer		
(Street) CAMBRIDGE, MA 02141	4. If Amendment, I Filed(Month/Day/Ye	-	A 	. Individual or Joi applicable Line) X_ Form filed by Or Form filed by Mo erson	ne Reporting Per	son
(City) (State) (Zip)	Table I - Non-	-Derivative Secur	rities Acqui	red, Disposed of,	or Beneficiall	v Owned
(Instr. 3) any (Mon	eemed 3. tion Date, if Transacti Code h/Day/Year) (Instr. 8)	4. Securities Ac ionor Disposed of ( (Instr. 3, 4 and 5	cquired (A) (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common 12/15/2015 Stock	М	1,000 A	\$ 2.09	1,000	D	
Common 12/15/2015 Stock	S <u>(1)</u>	1,000 D	\$ 58.5458 (2)	0	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

### Edgar Filing: bluebird bio, Inc. - Form 4

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number prof Derivativ Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	(Month/Day	Date	7. Title and Underlying a (Instr. 3 and	Securities	8. H Der Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 2.09	12/15/2015		М	1,00	) <u>(3)</u>	04/13/2022	Common Stock	1,000	

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Davidson David C/O BLUEBIRD BIO, INC. 150 SECOND STREET CAMBRIDGE, MA 02141			Chief Medical Officer		
Signatures					

Date

/s/Jason F. Cole,	12/17/2015
Attorney-in-Fact	12/1//2013

\*\*Signature of Reporting Person

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). \*\*
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 14, (1) 2015.
- The range of prices for the transaction reported on this line was \$58.50 to \$58.81. The average weighted price was \$58.5458. The (2) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option vests over a four-year period, at a rate of twenty-five percent (25%) on February 13, 2013 and in 36 equal monthly (3) installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.